[Pharmacological treatment of acute hepatitis B].

Abstract

The incidence of acute B hepatitis is decreasing due to socioeconomical changes and the implementation of vaccination programs. Nevertheless it is potentially severe, causing approximately 30% of acute liver failures in Spain. Pharmacological treatment of acute B hepatitis has become a matter of issue over the last decade. This text offers a review of the published data and international guidelines. Most published studies have a low methodological quality and lamivudine was used as treatment in all of them. A survival improvement with prompt treatment has been shown in acute liver injury and probably in severe acute hepatitis (total bilirubin>10mg/dl and INR>1.5). International guidelines support treatment in these cases, but there is no consensus on the drug to use or the length of treatment.

• Authors: Francisco Javier García-Alonso, Rosa María Martín-Mateos, Víctor Moreira Vicente
• Journal: Medicina clinica (Med Clin (Barc)) Vol. 138 Issue 14 Pg. 633-7 (May 19 2012) ISSN: 1578-8989 [Electronic] Spain
• Vernacular Title: Tratamiento farmacológico de la hepatitis B aguda.
• PMID: 22118973 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2011 Elsevier España, S.L. All rights reserved.

Chemical References

• Antiviral Agents
• Nucleosides
• Organophosphonates
• Pyrimidinones
• Telbivudine
• Lamivudine
• entecavir
• Guanine
• Tenofovir
• Adenine
• Thymidine

Topics

• Acute Disease
• Adenine (analogs & derivatives, therapeutic use)
• Antiviral Agents (therapeutic use)
• Guanine (analogs & derivatives, therapeutic use)
• Hepatitis B (diagnosis, drug therapy, epidemiology)
• Humans
• Lamivudine (therapeutic use)
• Nucleosides (therapeutic use)
• Organophosphonates (therapeutic use)
• Practice Guidelines as Topic
• Pyrimidinones (therapeutic use)
• Spain (epidemiology)
• Telbivudine
• Tenofovir
• Thymidine (analogs & derivatives)
• Treatment Outcome